Serping1 Antibody

What is SERPING1 and what is its biological function?

SERPING1, also known as C1 Inhibitor (C1INH), is a member of the Serine proteinase inhibitor (serpin) family. Its primary function involves inhibition of the complement system, a key component of the immune response. The protein plays an essential role in regulating inflammatory processes by preventing excessive activation of the complement cascade . As a serpin family member, SERPING1 functions as a crucial regulatory protein that helps maintain immune homeostasis.

When functioning properly, SERPING1 prevents uncontrolled activation of complement pathways that could otherwise lead to tissue damage and inflammatory responses. Dysregulation of SERPING1 has been implicated in several pathological conditions, most notably hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling affecting various body parts . Understanding the biological function of SERPING1 is fundamental for researchers investigating immune regulation mechanisms and inflammatory diseases.

What are the common applications for SERPING1 antibodies in research?

SERPING1 antibodies serve multiple research applications with varying degrees of sensitivity and specificity. Western Blot (WB) applications typically employ dilutions ranging from 1:1000 to 1:4000, allowing researchers to detect SERPING1 protein in various sample types including human plasma, liver tissue, cell lines like HeLa and HepG2, and mouse liver tissue . This technique enables quantitative analysis of SERPING1 expression levels across different experimental conditions.

Immunohistochemistry (IHC) applications utilize dilutions between 1:200 and 1:800, with successful detection reported in human tonsillitis tissue and normal colon samples . For optimal results, antigen retrieval with TE buffer pH 9.0 is suggested, though citrate buffer pH 6.0 serves as an alternative. Immunofluorescence (IF) and immunocytochemistry (ICC) applications employ similar dilution ranges (1:200-1:800) and have been validated in cell lines like HepG2 . Each application has been documented in multiple peer-reviewed publications, confirming the reliability of SERPING1 antibodies across diverse experimental conditions.

How does SERPING1 relate to hereditary angioedema (HAE)?

Hereditary angioedema (HAE) is an autosomal dominant disease characterized by recurrent edema attacks with significant morbidity and mortality. The condition results from variations in the SERPING1 gene that encodes C1 inhibitor. In HAE type I patients, plasma levels of C1INH are reduced to approximately 20%-30% of normal levels, despite patients being heterozygous for the mutation . This reduction leads to enhanced activation of the contact system, triggering elevated bradykinin levels and increased vascular permeability.

The diagnostic criteria for HAE due to C1-INH deficiency involve specific laboratory parameters. Patients are diagnosed with C1-INH-HAE type I when both functional and antigenic C1-INH levels are ≤50% of normal values . In contrast, C1-INH-HAE type II is characterized by functional C1-INH ≤50% while antigenic C1-INH remains >50% of normal . Additional laboratory findings typically include reduced C4 antigen levels (≤50% of normal in 92.2% of patients), while C3 antigen levels generally remain within or slightly below normal range, and C1q levels remain normal . These diagnostic markers are crucial for researchers investigating the pathophysiology of HAE and developing targeted therapeutic approaches.

What cellular mechanisms explain the dominant-negative effect of mutant SERPING1 on protein secretion?

The cellular mechanisms underlying the dominant-negative effect of mutant SERPING1 involve complex protein-protein interactions between normal and mutant C1INH molecules. Research has revealed that certain HAE-causing SERPING1 alleles trigger the formation of these interactions, leading to the creation of larger intracellular C1INH aggregates that become trapped in the endoplasmic reticulum (ER) . This intracellular retention prevents the secretion of functional C1INH proteins, explaining the disproportionately low C1INH levels observed in heterozygous HAE type I patients.

Experimental evidence supporting this mechanism comes from cellular models based on ectopic expression of normal and mutated C1INH variants. When HepG2 cells (a human hepatocarcinoma cell line representing the primary site of C1INH production) were transfected with plasmids expressing HAE-causing SERPING1 variants, secretion of C1INH was severely reduced compared to cells transfected with wild-type SERPING1 . Importantly, increased intracellular C1INH levels were observed for all six tested variants, confirming that reduced secretion correlates with increased intracellular accumulation rather than reduced expression. Dose-response experiments further demonstrated that increasing amounts of mutant C1INH (particularly the c.551_685del variant) progressively blocked the cellular transport and secretion of normal C1INH protein, confirming the dominant-negative inhibitory effect .

What is the significance of the discrepancy between calculated and observed molecular weights of SERPING1?

The observed molecular weight of SERPING1 (100 kDa) differs substantially from its calculated molecular weight (55 kDa based on 500 amino acids) . This discrepancy represents an important consideration for researchers interpreting Western blot results. The significant difference between expected and observed molecular weights is primarily attributed to post-translational modifications, particularly glycosylation patterns that add considerable mass to the protein.

When conducting Western blot analysis of SERPING1, researchers should anticipate detecting bands at approximately 100 kDa under reducing conditions, as demonstrated in experiments with human lung and ovary tissue samples . This observation has been consistently reported across multiple studies and is considered a validation criterion for antibody specificity. The glycosylation profile of SERPING1 may vary slightly between tissue types and experimental conditions, potentially resulting in minor variations in observed molecular weight. Researchers should therefore consider this factor when troubleshooting unexpected band patterns or when comparing results across different experimental systems or antibodies.

How do specific SERPING1 mutations affect intracellular protein trafficking and secretion?

Different SERPING1 mutations exhibit varying effects on intracellular protein trafficking and secretion, contributing to the phenotypic heterogeneity observed in HAE. Experimental studies in both HepG2 and HeLa cells have demonstrated mutation-specific patterns of intracellular accumulation and secretion impairment . For instance, the c.551_685del variant demonstrates particularly severe impairment of normal C1INH secretion, suggesting this mutation creates a strong dominant-negative effect.

Cellular imaging studies have revealed that mutant C1INH proteins form aggregates within the endoplasmic reticulum, disrupting the normal secretory pathway. The severity of this disruption appears to be mutation-dependent, with some variants causing more profound retention than others. When wild-type C1INH is co-expressed with mutant variants, the normal protein can become trapped in these aggregates through protein-protein interactions, preventing its secretion. This mechanism explains the quantitative discrepancy observed in HAE type I patients, where C1INH plasma levels (20-30% of normal) are lower than the expected 50% for a heterozygous condition . The specific structural alterations caused by different mutations likely determine their capacity to form these protein-protein interactions and their subsequent impact on intracellular trafficking.

What are the optimal conditions for using SERPING1 antibodies in Western blot applications?

Successful Western blot detection of SERPING1 requires careful optimization of experimental conditions. The recommended dilution range for SERPING1 antibodies in Western blot applications is 1:1000 to 1:4000 . When working with human samples, researchers should anticipate detecting SERPING1 at approximately 100 kDa under reducing conditions, reflecting its extensively glycosylated state rather than its calculated molecular weight of 55 kDa .

For optimal results, the following methodological considerations should be implemented:

When troubleshooting Western blot experiments, consider that the glycosylation profile of SERPING1 may cause slight variations in migration patterns between different tissue types. Additionally, sample preparation methods may affect detection sensitivity, particularly if proteolytic degradation occurs during processing. Starting with established positive controls such as human plasma or liver tissue can help validate experimental conditions before proceeding to experimental samples.

What considerations are important when using SERPING1 antibodies in immunohistochemistry?

Immunohistochemical detection of SERPING1 requires specific technical considerations to achieve optimal staining with minimal background. The recommended dilution range for SERPING1 antibodies in IHC applications is 1:200 to 1:800 . Antigen retrieval represents a critical step, with TE buffer at pH 9.0 showing superior results, though citrate buffer at pH 6.0 provides an acceptable alternative .

Successful IHC detection of SERPING1 has been validated in human tonsillitis tissue and normal colon samples . When establishing IHC protocols, consider the following optimization strategies:

• Perform antibody titration experiments to determine the optimal concentration for your specific tissue type

• Include appropriate positive control tissues such as human liver or tonsil

• Implement parallel negative controls (omitting primary antibody) to assess background staining

• Consider the fixation method, as overfixation may mask epitopes and reduce staining intensity

• Adjust incubation times and temperatures based on preliminary results

For fluorescence-based detection methods (IF/ICC), similar dilution ranges apply (1:200-1:800), with validated detection in cell lines like HepG2 . When adapting protocols between brightfield and fluorescence microscopy, consider the different sensitivity thresholds and potential background sources specific to each technique.

How should SERPING1 antibodies be stored and handled to maintain optimal activity?

Proper storage and handling of SERPING1 antibodies are crucial for maintaining their specificity and sensitivity over time. Most commercial SERPING1 antibodies are supplied in liquid form with storage buffer containing PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . These formulations are designed to prevent microbial contamination while maintaining antibody stability during freeze-thaw cycles.

The following storage and handling guidelines will help maximize antibody performance:

• Store antibodies at -20°C for long-term storage, where they typically remain stable for one year after shipment

• Avoid repeated freeze-thaw cycles by preparing small aliquots upon initial thawing

• For antibodies containing 0.1% BSA (typically in smaller volume formulations), aliquoting may be unnecessary for -20°C storage

• Allow antibodies to equilibrate to room temperature before opening tubes to prevent condensation

• Centrifuge briefly before opening to collect solution at the bottom of the tube

• Handle with clean pipette tips to prevent contamination

• Return to -20°C promptly after use

When working with reconstituted lyophilized antibodies, they typically remain stable for approximately one month at 2-8°C under sterile conditions, or for six months at -20 to -70°C . Always consult the manufacturer's specific recommendations for the particular antibody formulation being used.

What are common issues when detecting SERPING1 in different sample types?

Researchers working with SERPING1 antibodies may encounter several common technical challenges across different sample types. When analyzing human plasma samples, the high abundance of SERPING1 (approximately 0.25 mg/ml) may cause signal saturation in Western blots, necessitating higher sample dilutions. Conversely, cellular samples may contain lower SERPING1 concentrations, requiring loading optimization or more sensitive detection methods.

Specific challenges and solutions for different sample types include:

When analyzing mutant SERPING1 variants, researchers should anticipate potential alterations in epitope accessibility that might affect antibody binding. Additionally, intracellular aggregation of mutant SERPING1 proteins may create detection artifacts in immunofluorescence experiments, appearing as punctate rather than diffuse staining patterns. These observations should be interpreted in the context of the known biology of SERPING1 mutants and their propensity to form ER-retained aggregates .

How can researchers validate the specificity of SERPING1 antibodies?

Validating antibody specificity is crucial for generating reliable and reproducible data in SERPING1 research. A comprehensive validation approach includes multiple complementary techniques to confirm that the detected signal genuinely represents SERPING1 protein.

The following validation strategies are recommended:

• Molecular Weight Verification: Confirm detection at the expected molecular weight (approximately 100 kDa for fully glycosylated SERPING1) in Western blot applications .

• Positive Control Samples: Include established positive controls such as human plasma, liver tissue, or HepG2 cells where SERPING1 expression has been well-documented .

• Genetic Knockout/Knockdown: Compare signal between wild-type samples and those with reduced SERPING1 expression (siRNA knockdown) or complete absence (CRISPR knockout).

• Epitope Blocking: Pre-incubate antibody with excess immunizing peptide to demonstrate signal reduction in peptide-specific antibodies.

• Multiple Antibody Concordance: Verify results using different antibodies targeting distinct SERPING1 epitopes.

• Orthogonal Detection Methods: Correlate antibody-based detection with mRNA expression data from qPCR or RNA-seq.

For researchers working with disease-associated SERPING1 variants, validating antibody reactivity with specific mutant proteins is additionally important, as structural alterations might affect epitope accessibility or antibody binding properties.

What factors influence the interpretation of SERPING1 detection in HAE patient samples?

Interpreting SERPING1 detection in samples from HAE patients requires careful consideration of multiple variables that might influence results. The distinction between HAE type I (reduced antigenic and functional C1INH) and type II (normal or elevated antigenic but reduced functional C1INH) necessitates complementary analytical approaches combining quantitative and functional assessments.

Key factors affecting interpretation include:

• Sample Timing: C1INH levels may fluctuate during acute attacks; standardized sampling during remission periods provides more consistent baseline measurements.

• Medication Effects: Some treatments may increase C1INH levels; documentation of current treatments is essential for accurate interpretation.

• Mutation Type: Different SERPING1 mutations cause varying degrees of protein misfolding and intracellular retention, resulting in heterogeneous detection patterns .

• Detection Method Sensitivity: ELISA methods may have different detection thresholds compared to Western blot; standardized assays are preferable for diagnostic applications.

• Complement Activation: Reduced C4 levels (observed in 92.2% of patients) serve as an indirect indicator of C1INH functional deficiency and complement activation .

• Age Considerations: Pediatric patients may have different baseline levels compared to adults; age-appropriate reference ranges should be applied.

When analyzing samples from families with HAE, researchers should note that eight patients in one study were diagnosed before symptom onset based on SERPING1 gene analysis , highlighting the value of genetic testing in pre-symptomatic diagnosis and research cohort characterization.

What emerging technologies are enhancing SERPING1 research?

Advanced technological approaches are expanding the toolkit available for SERPING1 research beyond traditional antibody-based methods. CRISPR-Cas9 gene editing enables precise modification of SERPING1 to create cellular models that recapitulate disease-causing mutations. This approach allows researchers to study the effects of specific mutations on protein folding, trafficking, and function in physiologically relevant cellular contexts.

High-resolution imaging techniques such as super-resolution microscopy and correlative light and electron microscopy (CLEM) provide unprecedented visualization of SERPING1 intracellular trafficking and aggregation. These methods can reveal subcellular localization patterns with nanometer precision, offering new insights into the mechanisms of protein retention in the endoplasmic reticulum. Complementary approaches using fluorescence recovery after photobleaching (FRAP) or photoactivatable fluorescent proteins can assess protein mobility and aggregation dynamics in living cells.

Mass spectrometry-based proteomics represents another frontier, enabling comprehensive analysis of SERPING1 post-translational modifications, interaction partners, and structural alterations caused by disease-associated mutations. These approaches can identify novel regulatory mechanisms and potential therapeutic targets that might not be accessible through antibody-based detection methods alone.

How can SERPING1 antibodies contribute to therapeutic development for HAE?

SERPING1 antibodies serve as essential tools in the development and evaluation of therapeutic strategies for hereditary angioedema. Beyond their diagnostic utility, these antibodies enable researchers to assess the efficacy of experimental therapies designed to correct protein folding, enhance secretion, or supplement C1INH levels. When evaluating potential therapeutics targeting the dominant-negative effect of mutant SERPING1, antibodies provide crucial readouts of intracellular retention and secretion recovery.

For gene therapy approaches aiming to deliver functional SERPING1 genes, antibodies allow quantification of therapeutic protein expression and distribution. Similarly, for RNA-based therapeutics like antisense oligonucleotides designed to suppress mutant SERPING1 allele expression, antibodies enable assessment of selective protein reduction. In drug discovery pipelines targeting the unfolded protein response or proteostasis regulators, SERPING1 antibodies serve as primary screening tools to identify compounds that enhance mutant protein folding and secretion.

The development of more sensitive and specific antibodies, particularly those that can distinguish between wild-type and mutant SERPING1 proteins, would further accelerate therapeutic research by enabling direct assessment of allele-specific interventions. Such tools would be invaluable for personalized medicine approaches tailored to specific SERPING1 mutations.